Orencia abatacept regulatory update

Bristol-Myers disclosed in its 3Q10 earnings that Japan's Ministry of Health, Labor and Welfare approved an NDA in July for Orencia abatacept to treat rheumatoid arthritis. The CTLA-4 Ig fusion prote...